Company Overview of ADC Therapeutics Sarl
ADC Therapeutics Sarl develops antibody drug conjugates (ADCs) and non-antibody drug conjugate products. The company is based in Lausanne, Switzerland. ADC Therapeutics Sarl operates as a subsidiary of Celtic Therapeutics Holdings L.P.
Key Executives for ADC Therapeutics Sarl
Chief Executive Officer and Director
Senior Vice President of Research & Development
Compensation as of Fiscal Year 2013.
ADC Therapeutics Sarl Key Developments
MedImmune Enters into Collaboration Agreement with ADC Therapeutics
Oct 15 13
MedImmune has also entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADC Therapeutics' antibody-drug conjugate programmes in preclinical development. The collaboration agreement will include an upfront payment with predetermined development milestones for two programmes from a defined list and a cost- and profit-sharing arrangement with MedImmune representing the majority share. ADC Therapeutics will also have the option to co-promote one of the products in the US.
ADC Therapeutics Sarl Licenses Proprietary Antibody from BZL Biologics LLC for Prostate Cancer
Jul 15 13
ADC Therapeutics Sarl and BZL Biologics LLC announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers. PSMA is a cell-surface antigen on prostate cancer cells, and PSMA levels correlate directly with an aggressive, metastasizing phenotype. The characteristics of PSMA - its cancer specificity, presence in 95% of prostate cancers, high level of expression, and rapid internalization -make it an ideal ADC target. ADC Therapeutics plans to initiate pre-IND development of a PSMA-specific ADC immediately, adding to ADC Therapeutics' portfolio of proprietary ADC programs. Its unique platform combines monoclonal antibodies specific to particular types of tumor cells, in this case PSMA, with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As ADC Therapeutics PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.
VivaMab and ADC Therapeutics Sarl Announces Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers
Jun 24 13
VivaMab and ADC Therapeutics Sarl announced a licensing deal for a novel antibody against an undisclosed hematological cancer target. Under the terms of the deal, ADC Therapeutics has licensed a VivaMab antibody (VM101) produced using BioAtla's Express Humanization(TM), Comprehensive Positional Evolution(TM), Combinatorial Protein Synthesis(TM) affinity and functional maturation technology platforms. VM101 has been combined with a third-generation cytotoxic pyrrolobenzodiazepine (PBD)-based warhead and proprietary linker technology to form a novel ADC, which has already been shown to have powerful in vivo efficacy in established models for normally intractable hematological cancer indications. ADC Therapeutics plans to initiate pre-IND development of this proprietary ADC immediately, in parallel with its other advanced ADC programs. VivaMab will provide development support and will receive a share of potential milestones and royalties on the drug. Financial terms were not disclosed and remain confidential.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 15, 2013
Most Searched Private Companies
Sponsored Financial Commentaries